Bringing the power of semiconductor technologies to life sciences
November 6, 2024 | Nihonbashi Life Science HUB, Nihonbashi Muromachi, 1-5-5, Chuo-ku, 8F., Muromachi Chibagin Mitsui Building
Semiconductor technologies are transforming all aspects of healthcare, from research and pharma manufacturing to prevention, diagnostics, and therapeutics. Join hosts and co-organizers imec, LINK-J, and JMAC, with the support of METI, at the inaugural edition of imec’s health symposium.
Why Attend?
This half-day symposium will discuss how semiconductor technologies are transforming life sciences, pharma and biotech, and how companies at the forefront of innovation can work with imec to leverage its unique R&D, prototyping, and manufacturing services. Imec is proud to be a longstanding partner for many leading companies across the Japanese industry and commits to further support Japan’s ambitions.
- Learn how imec is using its pivotal role in semiconductor R&D to work with leading innovators in healthcare.
- Get an update on imec’s latest developments for life sciences, pharma and biotech, specifically in cell & gene therapy and biomanufacturing.
- Learn how to leverage imec’s deep-tech expertise and infrastructure, supported by the 400M EUR independent deep-tech venture fund imec.xpand.
- Engage with industry experts, business leaders, and innovators from the semiconductor and life sciences industry.
Agenda
- 12:30 - Registration & welcome coffee
- 13:25 - Welcome by Katrien Marent, EVP & Chief Marketing and Communications Officer at imec
- 13:30 - Opening remarks by:
- Luc Van den hove, President & CEO at imec
- Hirokazu Shimoda, Director, Bio-Industry Division (Commerce and Service Industry Policy Group) at METI
- Akihiko Soyama, President & CEO at LINK-J
- Hiroki Nakae, Director General at JMAC
- 13:50 - Impact of Semiconductors on Life Science Innovation in Japan by Akihiko Soyama, President & CEO at LINK-J
- 14:10 - Bringing the power of semiconductor technologies to the life sciences by Paru Deshpande, Vice President R&D Life Sciences Technologies at imec
- 14:40 - Expansion of the bio-industry and international standardization by Hiroki Nakae, Director General at JMAC
- 15:10 - Raising the bar in cell therapy manufacturing: on-chip systems for high-throughput, selective cell selection and manipulation by Liesbet Lagae, Fellow Life Sciences at imec
- 15:30 - Miniaturizing for impact: how semiconductors power mass customization and unlock access to life-saving cell therapies by Daniela Buchmayr, CEO & Co-founder at Sarcura
- 15:50 - Networking break
- 16:30 - Bringing real-time inline/online monitoring to biomanufacturing: imec’s toolbox for process analytical technologies by Bert Verbruggen, Program Manager Biomanufacturing Solutions at imec
- 17:00 - Building a prime deep-tech venturing ecosystem on the shoulders of a global tech leader by Olivier Rousseaux, Director-Venture Development at imec
- 17:30 - Closing remarks
- 17:35 - Networking reception
- 19:30 - End
Speakers
Katrien Marent - EVP & Chief Marketing and Communications Officer, imec
Katrien Marent became imec's VP corporate, marketing and outreach communication in 2016. Since April 2020, she is Executive Vice President & Chief Marketing and Communications Officer, and member of the executive board of imec. Katrien has an engineering degree in microelectronics. She joined imec in 1992 as an analog design engineer and specialized in design of low-noise readout electronics for high-energy physics.
Luc Van den hove - President & CEO, imec
Luc Van den hove has been President and CEO of imec since July 2009. He joined imec in 1984 and held various leadership roles before becoming CEO, including Executive Vice President and Chief Operating Officer. He holds a PhD in Electrical Engineering from KU Leuven, Belgium. In 2023, Luc received the Robert N. Noyce Medal for his contributions to the global research ecosystem in nanoelectronics. He has authored over 200 publications.
Hirokazu Shimoda - Director, Bio-Industry Division (Commerce and Service Industry Policy Group), METI
Hirokazu Shimoda is Director of the Bio-Industry Division within the Commerce and Service Industry Policy Group at METI (the Ministry of Economy, Trade and Industry in Japan). Since joining METI in 1999, he has contributed to IT policy, cybersecurity, and biotechnology innovation, and has developed compensation standards and industrial policies for biotech and regenerative medicine. He has served as Executive Director at JETRO in San Francisco and as a fellow at the World Economic Forum. He holds a degree in Electronic and Physical Engineering from the Tokyo Institute of Technology.
Akihiko Soyama - President & CEO, LINK-J
Akihiko Soyama has been CEO of LINK-J since its founding in 2016. Previously, he held executive roles at METI, Boston Consulting Group, Johnson & Johnson Japan, and others. He holds an MBA from Columbia University and a BS in Physics from the University of Tokyo. Akihiko also serves as a professor at Tohoku University and is active in various government and industry committees.
Hiroki Nakae - Director General, JMAC
Hiroki Nakae has a background in biological research, with published work in immunohistochemistry, neuroscience, and molecular biology. He has experience in business and venture startups and is currently engaged in national projects and ISO standard development at JMAC.
Paru Deshpande - VP R&D Life Sciences Technologies, imec
Paru Deshpande completed his PhD at Princeton University in polymer self-assembly for lithography. He was the first employee at BioNano Genomics, where he led projects in single-molecule DNA detection and assay development. In 2012, Paru joined imec, where he is currently Vice President of Life Science Technologies, overseeing the department’s R&D efforts.
Liesbet Lagae - Fellow, Life Sciences, imec
Liesbet Lagae is a co-founder and Program Director of Life Science Technologies at imec, where she initiated the field of molecular and cellular biochips leveraging silicon technologies. She holds a PhD from, and is a part-time professor in nanobiotechnology at KU Leuven in Belgium. She has authored 125 peer-reviewed papers, holds 15 patents, and is recipient of a prestigious ERC Consolidator Grant for developing a platform on single-cell analysis and sorting.
Daniela Buchmayr - CEO and Co-Founder, Sarcura
Daniela Buchmayr is CEO and Co-Founder of Sarcura, a Vienna-based startup focused on scaling cell therapy manufacturing. With over 15 years of biopharmaceutical experience, Daniela drives Sarcura’s strategic direction. She holds an MBA in Innovation & Entrepreneurship and an engineering degree in Biochemistry, Biotechnology, and Genetics.
Bert Verbruggen - Program Manager, Biomanufacturing Solutions, imec
Bert Verbruggen is Program Manager for Biomanufacturing Solutions at imec, where he leads projects on biomanufacturing technologies, process analytical technologies, and diagnostics. He began his scientific career with a master’s in bio-nano technology (bio-engineering) at the University of Leuven, followed by a PhD on biosensors and microfluidics. He has led the development of multiple medical products, from early exploration to product launch.
Olivier Rousseaux - Director Venture Development, imec
Olivier Rousseaux is the Director of Venture Development at imec. He holds a PhD in Electrical Engineering from KU Leuven and an EMBA from Solvay Business School. Olivier has a background in wireless communications and venture creation and previously held roles in corporate strategy and business line management at Commscope.
Location
Nihonbashi Life Science HUB
Nihonbashi Muromachi, 1-5-5, Chuo-ku, Tokyo 103-0022
8F., Muromachi Chibagin Mitsui Building
共催者
Registration
Thank you for your interest. Online registrations are now closed. You can still join us by registering onsite (subject to availability).